Alexion Pharmaceuticals (NASDAQ:ALXN) will report earnings before markets open on Thursday, July 25th. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
Here is your Cheat Sheet to Alexion Pharmaceuticals Earnings:
Earnings Expectations: Analysts expect earnings of $0.68 per share on revenues of $365.04 million. Currently, the company’s P/E ratio stands at 76.58.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $0.76 to a profit $0.78. For the current year, the average estimate is a profit of $2.96, which is better than the estimate ninety days ago.
Here’s how Alexion Pharmaceuticals has been performing on an annual basis:
|Revenue ($) in millions||259||387||541||783||1,134|
|Diluted EPS ($)||0.19||1.63||0.52||0.91||1.28|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||274.72||294.14||320.53||338.94|
|Diluted EPS ($)||0.18||0.46||0.40||0.41|
Alexion Pharmaceuticals has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)